The Play On Bristol-Myers Squibb

Core Viewpoint - Shares of Bristol-Myers Squibb Company (NYSE: BMY) have declined approximately 30% from their peak in March, despite the company raising its FY25 outlook twice following two quarterly earnings beats, indicating market concerns about its growth prospects [2]. Group 1: Company Performance - Bristol-Myers Squibb has raised its FY25 outlook twice after reporting two consecutive quarterly earnings beats [2]. - The stock has experienced a significant decline of around 30% from its year-high peak in March [2]. Group 2: Market Sentiment - The market is increasingly worried that Bristol-Myers Squibb may lack sufficient growth drivers, contributing to the stock's decline [2].